Market closedNon-fractional
vTv Therapeutics/VTVT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About vTv Therapeutics
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
Ticker
VTVT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
High Point, United States
Employees
16
Website
vtvtherapeutics.com
vTv Therapeutics Metrics
BasicAdvanced
$51M
Market cap
-
P/E ratio
-$7.93
EPS
0.52
Beta
-
Dividend rate
Price and volume
Market cap
$51M
Beta
0.52
Financial strength
Current ratio
6.039
Quick ratio
5.975
Long term debt to equity
0.481
Total debt to equity
1.147
Interest coverage (TTM)
-1,823.23%
Management effectiveness
Return on assets (TTM)
-35.69%
Return on equity (TTM)
-198.61%
Valuation
Price to revenue (TTM)
54.607
Price to book
2.99
Price to tangible book (TTM)
2.99
Price to free cash flow (TTM)
-2.57
Growth
Revenue change (TTM)
5,455.56%
Earnings per share change (TTM)
-3.68%
3-year revenue growth (CAGR)
-48.67%
3-year earnings per share growth (CAGR)
7.62%
vTv Therapeutics Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1M
∞%
Net income
-$4.8M
41.18%
Profit margin
-480.00%
-∞%
vTv Therapeutics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.00
-$0.00
-$0.00
-$1.67
Expected
-
-
-
-
Surprise
-
-
-
-
vTv Therapeutics News
AllArticlesVideos
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
GlobeNewsWire·7 hours ago
vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes
GlobeNewsWire·1 month ago
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
PRNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for vTv Therapeutics stock?
vTv Therapeutics (VTVT) has a market cap of $51M as of July 27, 2024.
What is the P/E ratio for vTv Therapeutics stock?
The price to earnings (P/E) ratio for vTv Therapeutics (VTVT) stock is 0 as of July 27, 2024.
Does vTv Therapeutics stock pay dividends?
No, vTv Therapeutics (VTVT) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next vTv Therapeutics dividend payment date?
vTv Therapeutics (VTVT) stock does not pay dividends to its shareholders.
What is the beta indicator for vTv Therapeutics?
vTv Therapeutics (VTVT) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell vTv Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.